Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Jay Flatley, Greg Heath, Justin Johnson, Fei Lu, Biserka Bacic-Toplek, More


Illumina announced changes to its organization, including the reshuffling of current employees and new hires, that will take effect on Jan. 1, 2014.

President and CEO Jay Flatley will continue to serve as CEO, but the company will separate the two positions and appoint a new president.

The company is also reorganizing into five business units. Kirk Malloy, currently VP of Customer Solutions, will head the Life Sciences business unit. Tristan Orpin, currently chief commercial officer, will head the Reproductive and Genetic Health business unit. Christian Henry, currently SVP and general manager of the Genomic Solutions business will take over as chief commercial officer.

Rick Klausner, Illumina's chief medical officer, will serve as interim leader of the Oncology business unit. Nick Naclerio will head the Enterprise Informatics business unit, while continuing in his current role as SVP of corporate development. Finally, Illumina's newly created New and Emerging Markets business unit will be headed by Matt Posard, currently SVP and general manager of Illumina's Translational and Consumer Genomics.

Additionally, Greg Heath will move from his position as SVP and general manager of Illumina's Diagnostics business unit to SVP of IVD Development. Bob Ragusa will join the company in December as SVP of Operations.

Quality and Regulatory Affairs will become two separate functions with Regulatory Affairs being folded into IVD Development. Melina Cimler will serve as VP of Quality.

Justin Johnson is now the principal translational genomic scientist at AstraZeneca.

Previously, Johnson was director of bioinformatics, genomic services, and IT at EdgeBio where he was responsible for constructing data analysis pipelines and infrastructure. Other jobs he held prior to that include bioinformatics manager at J. Craig Venter Institute and a project manager at the Institute for Genomic Research.

Fei Lu, previously the CEO of SeqWright, which was bought by GE Healthcare last year, is now an independent consultant. Prior to her position at SeqWright, she was President and CEO of BioWright and general manager of Wilbury Partners.

Genewiz has expanded its European operations, opening Genewiz Germany. The firm has appointed Biserka Bacic-Toplek to sales executive to lead the company's Germany business operations.

The Translational Genomics Research Institute has named former US Surgeon General Richard Carmona to serve on its National Advisory Committee on rare childhood disorders. TGen announced the appointment this week in connection with the ribbon-cutting of a new clinical center in its Center for Rare Childhood Disorders.

Carmona will serve on NAC's Scientific-Medical Advisory Sub-Committee, which is focused on helping geneticists and healthcare professionals work together to incorporate genomic technologies into clinical care. Carmona, who currently is president of the Canyon Ranch Institute, was appointed US surgeon general in 2002 by President George W. Bush.

The College of American Pathologists swore in Gene Herbek as its new president on Oct. 12 at a ceremony in Orlando, Fla. Herbek, an active member of the national pathology organization for more than two decades, is CAP's 33rd president. He is medical director of two Omaha, Neb.-based labs, the Methodist Women's Hospital laboratory and the Pathology Center at Methodist Hospital.

Herbek takes over the presidency from Stanley Robboy.